1
|
Longo R, Mammoud SB, Ribal R, Dadoun A, Egea J, Plastino F, Legros PO, Marcon N, Liegeon AL, Campitiello M. A metastatic, cutaneous mucinous carcinoma revealed by the 16α- 18 F-fluoroestradiol ( 18 F-FES) PET/CT scan and successfully treated by hormonotherapy: Description of a case report. J Dermatol 2024. [PMID: 38216980 DOI: 10.1111/1346-8138.17111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Revised: 12/16/2023] [Accepted: 12/26/2023] [Indexed: 01/14/2024]
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Sinan Ben Mammoud
- Division of Nuclear Medicine, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Romane Ribal
- Division of Medical Oncology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Alexandre Dadoun
- Division of Medical Oncology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Julie Egea
- Division of Medical Oncology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | | | - Nathalie Marcon
- Department of Pathology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | | | - Marco Campitiello
- Division of Medical Oncology, "CHR Metz-Thionville", Ars-Laquenexy, France
| |
Collapse
|
2
|
Longo R, Colin S, Streiff C, Benichou CG, Wendel C, Campitiello M, Plastino F, Bastien C, Egea J. A primary small cell neuroendocrine carcinoma (SCNC) of the oral cavity (cheek mucosa): Description of a case report. Oral Oncol 2023; 137:106295. [PMID: 36565487 DOI: 10.1016/j.oraloncology.2022.106295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Accepted: 12/18/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Small cell neuroendocrine carcinoma (SCNC) of the oral cavity is a poorly differentiated, high-grade and very aggressive tumor with a poor prognosis. CASE DESCRIPTION A 64-year-old, Caucasian, smoker man consulted for an ulcero-necrotic, exophytic, lesion of the right retromolar trigone. Haed&neck CT scan showed a right tonsillar tumor lesion. The 18F-PET scan confirmed the presence of a right, highly hypermetabolic tonsillar lesion and two homolateral, cervical lymph nodes. Histology and immunohistochemistry were consisted with the diagnosis of a primary SCNC of the oral cavity. As the tumor was locally advanced and unresectable, the patient underwent a definitive radio-chemotherapy with a cisplatin/etoposide combined regimen (4 cycles). The treatment was well tolerated and led to a complete tumor response. CONCLUSION The particularity of this case relies on the rarity of the oral SCNC, its difficult and challenging diagnosis, and the complexity of its management that is not validated by large clinical trials, data being extrapolated from small cell lung cancer. In our case, the patient presenting a locally advanced tumor was treated by a combined radio-chemiotherapy leading to a complete tumor regression. The patient's follow up is too short to assess the real benefit of this treatment on overall survival.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Sebastien Colin
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Camille Streiff
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Claire Gamelon Benichou
- Division of Radiotherapy, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Chloé Wendel
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Marco Campitiello
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Francesca Plastino
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Claire Bastien
- Division of Pathology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| | - Julie Egea
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085 Ars-Laquenexy, France.
| |
Collapse
|
3
|
Longo R, Thiebaut V, Legros PO, Campitiello M, Plastino F, Goetz C, Margineanu B, Pujois J, Gunther M, Egea J, Wendel C. Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study. Acta Oncol 2022; 61:1394-1399. [PMID: 36228137 DOI: 10.1080/0284186x.2022.2132115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France
| | - Victoire Thiebaut
- Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France
| | | | - Marco Campitiello
- Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France
| | - Christophe Goetz
- Clinical Research Support Unit, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Bogdan Margineanu
- Division of Gynecology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Julie Pujois
- Division of Gynecology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Michel Gunther
- Division of Gynecology, "CHR Metz-Thionville", Ars-Laquenexy, France
| | - Julie Egea
- Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France
| | - Chloé Wendel
- Division of Medical Oncology, "CHR Metz-Thionville", Ars- Laquenexy, France
| |
Collapse
|
4
|
Longo R, Wagner M, Savenkoff B, de Castaing MC, Desiro G, Tubail Z, Hennequin L, Mahmoud SB, Marcon N, Quetin P, Campitiello M, Plastino F. Correction to: A paraneoplastic limbic encephalitis from an anorectal small cell neuroendocrine carcinoma: a case report. BMC Neurol 2022; 22:81. [PMID: 35260083 PMCID: PMC8903562 DOI: 10.1186/s12883-022-02598-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.
| | - Marc Wagner
- Division of Neurology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Benjamin Savenkoff
- Division of Nephrology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | | | - Guillaume Desiro
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Zead Tubail
- Division of Nephrology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Laurent Hennequin
- Division of Radiology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Sinan Ben Mahmoud
- Division of Nuclear Medecine, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Nathalie Marcon
- Division of Pathology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Philippe Quetin
- Division of Radiotherapy, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| |
Collapse
|
5
|
Longo R, Colin S, Streiff C, Wendel C, Bonhomme A, Sava C, Campitiello M, Plastino F, Egea J. A fatal primary gastric melanoma treated by a double immunotherapy with ipilimumab/nivolumab: description of a case report. J Gastrointest Oncol 2022; 13:2615-2619. [PMID: 36388646 PMCID: PMC9660087 DOI: 10.21037/jgo-22-79] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 08/12/2022] [Indexed: 12/02/2022] Open
Abstract
Background Primary gastric melanoma (GM) is a very uncommon tumor with a poor prognosis. Until now, only a few cases have been reported in the literature. Case Description A 70-year-old, Caucasian, ex-smoker man, presented with asthenia, anorexia, and weight loss of 5 kg during the last 2 months. Biological test showed high levels of transaminases and a microcytic, hypochromic anemia. Whole body CT-scan documented a gastric tumor lesion with concomitant loco-regional lymph node and hepatic metastases. Histology was consisted with the diagnosis of a primary GM. A double immunotherapy with nivolumab and ipilimumab was started but, 2 weeks later, the patient presented an acute hepatic failure quickly leading to his death despite a high dose corticotherapy. Conclusions The particularity of this case relies on the rarity of GM, its difficult diagnosis representing a clinical challenge, and the complexity of its management that is not validated by large clinical trials, data being extrapolated from the treatment protocols routinely used in cutaneous melanoma. In our case, the patient died 2 weeks after the first cycle of a nivolumab/ipilimumab combined treatment for an acute hepatic failure that could be related to a treatment toxicity or a tumor hyperprogression. The patient’s survival was very short not allowing any accurate evaluation of the efficacy of this therapy.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Sebastien Colin
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Camille Streiff
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Chloé Wendel
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Axelle Bonhomme
- Division of Dermatology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Claudia Sava
- Division of Gastoenterology, “H. Robert Schuman”, Metz-Vantoux, France
| | - Marco Campitiello
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| | - Julie Egea
- Division of Medical Oncology, “CHR Metz-Thionville”, Ars-Laquenexy, France
| |
Collapse
|
6
|
Longo R, Legros P, Talbi M, Wagner M, Paraschiv E, Campitiello M, Plastino F, Rozzi A. HER2-positive metastatic, parotid salivary duct carcinoma treated with a trastuzumab/pertuzumab-based chemotherapy: A case report. Clin Case Rep 2020; 8:2878-2882. [PMID: 33363842 PMCID: PMC7752417 DOI: 10.1002/ccr3.3209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Accepted: 07/08/2020] [Indexed: 11/05/2022] Open
Abstract
This case highlights the rare entity, salivary duct carcinoma (SDC), which is difficult to diagnose and manage. It is the first published case of a metastatic, HER2-positive parotid SDC successfully treated by a dual anti-HER2 treatment associated to a chemotherapy.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology“CHR Metz‐Thionville”Ars‐LaquenexyFrance
| | | | - Marouane Talbi
- Division of Plastic surgery“CHR Metz‐Thionville”Ars‐LaquenexyFrance
| | - Marc Wagner
- Division of Neurology“CHR Metz‐Thionville”Ars‐LaquenexyFrance
| | | | - Marco Campitiello
- Division of Medical Oncology“CHR Metz‐Thionville”Ars‐LaquenexyFrance
| | | | - Antonio Rozzi
- Division of Medical Oncology“CHR Metz‐Thionville”Ars‐LaquenexyFrance
| |
Collapse
|
7
|
Abstract
BACKGROUND Breast metastasis (BM) is extremely rare. Ovarian cancer accounts for approximately 0.03% to 0.6% of all BMs. BM diagnosis is challenging and the prognosis very poor. The treatment is multidisciplinary and strictly related to multiple clinical and biological factors. CASE REPORT A 70-year-old non-smoking Caucasian woman was hospitalized for a 4-month history of abdominal pain, anorexia, and weight loss of 10 kg. During the clinical examination, we found multiple axillary lymph nodes and a painless tumor lesion in the superior internal quadrant of the right breast. Whole body CT-scan and ¹⁸F-fluorodeoxyglucose PET scan documented a right ovarian tumor associated with multiple metastases, a hypermetabolic lesion of the right breast, and multiple axillary lymphadenopathies that were confirmed by breast ultrasonography. The percutaneous biopsy of both the right axillary lymph node and breast tumor showed a metastasis from a high-grade serous papillary ovarian adenocarcinoma. Considering the tumor aggressiveness and the lack of BRCA1 and BRCA2 mutations, we started systemic chemotherapy with a 3-week carboplatin/paclitaxel regimen combined with bevacizumab, which quickly improved the patient's symptoms and induced a biological tumor response. CONCLUSIONS This case reports a synchronous breast metastasis from an ovarian cancer and highlights this uncommon entity, which is very difficult to diagnose and treat. A differential diagnosis from a primary breast cancer should be considered as the treatment and prognosis of these 2 tumors are different.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Claire Bastien
- Division of Pathology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Antonio Rozzi
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| |
Collapse
|
8
|
Longo R, Jaud C, Gehin W, Hennequin L, Bastien C, Campitiello M, Rozzi A, Plastino F. Renal Metastases from a Nasal Cavity Mixed Squamous Cell and Adenoid Cystic Carcinoma: A Case Report. Am J Case Rep 2020; 21:e919781. [PMID: 31911575 PMCID: PMC6977623 DOI: 10.12659/ajcr.919781] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Patient: Female, 64-year-old Final Diagnosis: Renal metastases from a nasal cavity mixte • squamous cells and adenoid cystic • carcinoma Symptoms: Epistaxis Medication: — Clinical Procedure: — Specialty: Oncology
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - Camille Jaud
- Division of Medical Oncology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - William Gehin
- Division of Medical Oncology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - Laurent Hennequin
- Division of Radiology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - Claire Bastien
- Division of Pathology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - Antonio Rozzi
- Division of Medical Oncology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, "Centre Hospital Regional (CHR) Metz-Thionville", Ars-Laquenexy, France
| |
Collapse
|
9
|
Longo R, Wagner M, Savenkoff B, de Castaing MC, Desiro G, Tubail Z, Hennequin L, Mahmoud SB, Marcon N, Quetin P, Campitiello M, Plastino F. A paraneoplastic limbic encephalitis from an anorectal small cell neuroendocrine carcinoma: a case report. BMC Neurol 2019; 19:304. [PMID: 31783737 PMCID: PMC6884799 DOI: 10.1186/s12883-019-1542-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Accepted: 11/25/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Paraneoplastic limbic encephalitis (PLE) is a rare autoimmune neurological syndrome observed in cancer patients. PLE is difficult to diagnose and presents a variable response to treatment, depending on the characteristics of the tumor and neuronal autoantibodies. CASE PRESENTATION A 64-year-old, Caucasian, non-smoker man presented with a rapidly developing cognitive impairment, personality change, spatial disorientation, and short-term memory loss associated with anorexia and cervical and inguinal lymph nodes. The 18F-FDG PET scan documented intensely hypermetabolic lymph nodes, which histologically corresponded to a metastasis from a small cell neuroendocrine carcinoma. The brain MRI revealed a high T2-weighted FLAIR signal of the hippocamps, consisted with a PLE. The presence of anti-neuronal Hu antibodies confirmed the diagnosis. The patient underwent plasmapheresis, associated to a systemic chemotherapy resulting in a partial and temporary improvement of the neurological symptoms. Four cycles of intravenous immunoglobulins were also necessary. After six cures of chemotherapy, the lymph node metastases regressed. However, a new anorectal lesion was detected and was histologically confirmed as a primary small cell neuroendocrine carcinoma, which was treated with concomitant chemoradiotherapy. At the end of this treatment, the patient showed a rapid tumor progression leading to his death. CONCLUSIONS This case highlights the rare entity, PLE, which is difficult to diagnose and manage. In addition, this is the first published case of PLE associated with an anorectal small cell neuroendocrine carcinoma, which appeared after completion of systemic chemotherapy.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France.
| | - Marc Wagner
- Division of Neurology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Benjamin Savenkoff
- Division of Nephrology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | | | - Guillaume Desiro
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Zead Tubail
- Division of Nephrology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Laurent Hennequin
- Division of Radiology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Sinan Ben Mahmoud
- Division of Nuclear Medecine, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Nathalie Marcon
- Division of Pathology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Philippe Quetin
- Division of Radiotherapy, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, "CHR Metz-Thionville", 1 Allée du Château, 57085, Ars-Laquenexy, France
| |
Collapse
|
10
|
Longo R, Balasanu O, Chastenet de Castaing M, Chatelain E, Yacoubi M, Campitiello M, Marcon N, Plastino F. A Spontaneous Regression of an Isolated Lymph Node Metastasis from a Primary Unknown Merkel Cell Carcinoma in a Patient with an Idiopathic Hyper-Eosinophilic Syndrome. Am J Case Rep 2018; 19:1437-1440. [PMID: 30510152 PMCID: PMC6287448 DOI: 10.12659/ajcr.911840] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Patient: Male, 69 Final Diagnosis: Spontaneous regression of a Lymph node metastasis Symptoms: Hypereosinophilia • inguinal mass Medication: — Clinical Procedure: — Specialty: Oncology
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Oana Balasanu
- Division of Hematology, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| | | | - Eric Chatelain
- Division of Surgery, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Mohammed Yacoubi
- Division of Radiotherapy, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Nathalie Marcon
- Division of Pathology, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, Ars-Laquenexy, France
| |
Collapse
|
11
|
Longo R, Dorvaux V, Chatelain E, Quétin P, Plastino F, Eid N, Marcon N, Hennequin L, Campitiello M. Peritoneal Myeloid Sarcoma in a Patient Treated for a Testicular Seminoma. Am J Case Rep 2018; 19:763-766. [PMID: 29955031 PMCID: PMC6055577 DOI: 10.12659/ajcr.910434] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Myeloid sarcoma is a rare extramedullary soft tissue neoplasm composed of myeloblastic cells, usually associated to hematologic tumor disorders and a poor prognosis. Its diagnosis is very difficult as radiological images are not specific. Histology and immunohistochemistry are necessary for an accurate diagnosis. CASE REPORT We report the case of 46-year-old, Caucasian, non-smoker male, treated in 2014 by orchiectomy and systemic chemotherapy for a stage IIB testicular seminoma. Considering the rapid increase of lactate dehydrogenase (LDH) levels without any evident medical reason, a computed tomography/positron emission tomography (CT/PET) scan was performed and revealing a diffuse, nodular, peritoneal tumor infiltration associated with multiple mesenteric and mediastinal adenopathies. Laparoscopy confirmed a diffuse tumor infiltration of the peritoneum. Histology and immunohistochemistry were consisted with the diagnosis of a myeloid monoblastic sarcoma. Cytology of bone marrow documented an monocytic acute myeloid leukemia. The patient started a systemic induction chemotherapy with high dose cytarabine and idarubicin that was complicated by an infectious pneumonia and colitis, and a grade IV thrombocytopenia leading to a brain subdural hemorrhage and quickly to patient's death. CONCLUSIONS We describe a rare, peritoneal, myeloid sarcoma in a young patient who had been treated by systemic chemotherapy for testicular seminoma 4 years earlier. The patient was clinically asymptomatic and presented only elevated LDH levels without any evident clinical reason. Considering the persistence of this biochemical abnormality, more investigations were performed leading to a diagnosis of peritoneal myeloid sarcoma associated with monocytic acute myeloid leukemia, probably secondary to the past chemotherapy.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Véronique Dorvaux
- Division of Hematology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Eric Chatelain
- Division of Digestive Surgery, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Philippe Quétin
- Division of Radiotherapy, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Nada Eid
- Division of Medical Oncology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Nathalie Marcon
- Division of Pathology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Laurent Hennequin
- Division of Radiodiagnostics and Medical Imaging, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Ars-Laquenexy, France
| |
Collapse
|
12
|
Longo R, Melgar E, Campitiello M, Plastino F, Eid N, Quirin I, Hennequin L, Grignon Y, Gunther M, Quétin P. Breast metastasis from squamous cell carcinoma of the oropharynx: a case report. J Med Case Rep 2017; 11:355. [PMID: 29268777 PMCID: PMC5740581 DOI: 10.1186/s13256-017-1500-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Accepted: 10/25/2017] [Indexed: 11/25/2022] Open
Abstract
Background Breast metastases from extramammary tumors are extremely rare, the most common primary tumors being contralateral breast carcinoma, followed by lung, gynecological, gastrointestinal, melanoma, and hematological cancers. Only a few cases deriving from head and neck squamous cell carcinoma have been reported in the literature to date. Case presentation We report a case of a 47-year-old Caucasian woman who presented to our hospital with a solitary breast lesion in the right upper external quadrant associated with multiple bone and visceral metastases. Two years before, she had undergone radical resection of a squamous cell carcinoma of the oropharynx (stage pT2, pN1), which was followed by adjuvant radiotherapy. Breast ultrasound showed a hypoechogenic tumor lesion of 4 cm in the right upper external quadrant that was associated with multiple axillary and infra-/supraclavicular adenopathies. A positron emission tomographic scan documented multiple visceral and bone metastases with a single hypermetabolic lesion of the right breast. The results of histology and immunohistochemistry were consistent with a metastasis from a squamous cell carcinoma. The patient died of acute respiratory insufficiency 1 month after her breast metastasis diagnosis and before starting any systemic antitumoral treatment. Conclusions Although breast metastases are extremely rare, they should be considered in any patient with a history of cancer and confirmed by histology and immunohistochemistry because they are very difficult to distinguish from other primary breast tumors based only on clinical and radiological features. There are no standardized treatment guidelines for breast metastasis management. Surgery and radiotherapy can play a role in symptom palliation, but they do not have any relevant impact on survival, the prognosis being poor, with an estimated overall survival less than 1 year from diagnosis.
Collapse
Affiliation(s)
- Raffaele Longo
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France.
| | - Emmanuelle Melgar
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Nada Eid
- Division of Medical Oncology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Isabelle Quirin
- Division of Radiology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Laurent Hennequin
- Division of Radiology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Yves Grignon
- Division of Pathology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Michel Gunther
- Division of Gynecology, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| | - Philippe Quétin
- Division of Radiotherapy, Centre Hospitalier Régional (CHR) Metz-Thionville, 1 Allée du Château, 57085, Ars-Laquenexy, France
| |
Collapse
|
13
|
Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, Plastino F, Gori S, Magarotto R, Carteni G, Chiurazzi B, Pavese I, Marchetti L, Zagonel V, Bergo E, Tonini G, Imperatori M, Iacono C, Maiorana L, Pinto C, Rubino D, Cavanna L, Di Cicilia R, Gamucci T, Quadrini S, Palazzo S, Minardi S, Merlano M, Colucci G, Marchetti P. Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget 2017; 8:79884-79896. [PMID: 29108370 PMCID: PMC5668103 DOI: 10.18632/oncotarget.20168] [Citation(s) in RCA: 198] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Accepted: 06/20/2017] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND In cancer patients, malnutrition is associated with treatment toxicity, complications, reduced physical functioning, and decreased survival. The Prevalence of Malnutrition in Oncology (PreMiO) study identified malnutrition or its risk among cancer patients making their first medical oncology visit. Innovatively, oncologists, not nutritionists, evaluated the nutritional status of the patients in this study. METHODS PreMiO was a prospective, observational study conducted at 22 medical oncology centers across Italy. For inclusion, adult patients (>18 years) had a solid tumor diagnosis, were treatment-naive, and had a life expectancy >3 months. Malnutrition was identified by the Mini Nutritional Assessment (MNA), appetite status with a visual analog scale (VAS), and appetite loss with a modified version of Anorexia-Cachexia Subscale (AC/S-12) of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT). FINDINGS Of patients enrolled (N=1,952), 51% had nutritional impairment; 9% were overtly malnourished, and 43% were at risk for malnutrition. Severity of malnutrition was positively correlated with the stage of cancer. Over 40% of patients were experiencing anorexia, as reported in the VAS and FAACT questionnaire. During the prior six months, 64% of patients lost weight (1-10 kg). INTERPRETATION Malnutrition, anorexia, and weight loss are common in cancer patients, even at their first visit to a medical oncology center.
Collapse
Affiliation(s)
| | - Simone Lucia
- Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy
| | - Alessio Farcomeni
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
| | - Vito Lorusso
- Department of Medical Oncology, National Cancer Research Centre Giovanni Paolo II, Bari, Italy
| | - Valeria Saracino
- Department of Medical Oncology, National Cancer Research Centre Giovanni Paolo II, Bari, Italy
| | - Carlo Barone
- Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, Rome, Italy
| | - Francesca Plastino
- Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, Rome, Italy
| | - Stefania Gori
- Medical Oncology Unit, Ospedale Sacro Cuore Don Calabria, Verona, Italy
| | - Roberto Magarotto
- Medical Oncology Unit, Ospedale Sacro Cuore Don Calabria, Verona, Italy
| | | | | | - Ida Pavese
- Oncology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy
| | - Luca Marchetti
- Oncology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy
| | - Vittorina Zagonel
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Eleonora Bergo
- Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Giuseppe Tonini
- Department of Oncology, University Campus Bio-Medico of Rome, Rome, Italy
| | - Marco Imperatori
- Department of Oncology, University Campus Bio-Medico of Rome, Rome, Italy
| | - Carmelo Iacono
- Department of Medical Oncology, Azienda Ospedaliera Civile - Maria Paternò Arezzo, Ragusa, Italy
| | - Luigi Maiorana
- Department of Medical Oncology, Azienda Ospedaliera Civile - Maria Paternò Arezzo, Ragusa, Italy
| | - Carmine Pinto
- Medical Oncology, Clinical Cancer Centre, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - Daniela Rubino
- Medical Oncology, Clinical Cancer Centre, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - Luigi Cavanna
- Department of Oncology-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - Roberto Di Cicilia
- Department of Oncology-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - Teresa Gamucci
- Medical Oncology Unit, S.S. Trinita Hospital, Sora, Italy
| | | | - Salvatore Palazzo
- Division of Medical Oncology, Mariano Santo Hospital, Azienda Ospedaliera, Cosenza, Italy
| | - Stefano Minardi
- Division of Medical Oncology, Mariano Santo Hospital, Azienda Ospedaliera, Cosenza, Italy
| | - Marco Merlano
- Medical Oncology, Oncology Department, S. Croce & Carle Teaching Hospital, Cuneo, Italy
| | - Giuseppe Colucci
- Medical Oncology Department, National Cancer Research Centre Giovanni Paolo II, Bari, Italy
| | - Paolo Marchetti
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology Sapienza, St. Andrea Hospital, Rome, Italy
- IDI-IRCCS, Rome, Italy
| | | |
Collapse
|
14
|
Andre H, Pesce N, Plastino F, Kvanta A. Human ex vivo model of iris angiogenesis. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.0t011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- H. Andre
- KarolinskaInstitutet, StErikEyeHospital; Stockholm Sweden
| | - N. Pesce
- KarolinskaInstitutet, StErikEyeHospital; Stockholm Sweden
| | - F. Plastino
- KarolinskaInstitutet, StErikEyeHospital; Stockholm Sweden
| | - A. Kvanta
- KarolinskaInstitutet, StErikEyeHospital; Stockholm Sweden
| |
Collapse
|
15
|
Wendel C, Campitiello M, Plastino F, Eid N, Hennequin L, Quétin P, Longo R. Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report. Am J Case Rep 2017; 18:7-11. [PMID: 28044054 PMCID: PMC5223779 DOI: 10.12659/ajcr.901032] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Pituitary metastasis is uncommon, breast and lung cancers being the most frequent primary tumors. Renal cell carcinoma (RCC) is a rare cause of pituitary metastases, with only a few cases described to date. CASE REPORT We report a case of a 61-year-old man who presented with a progressive deterioration of visual acuity and field associated with a bitemporal hemianopsia. Two years ago, he underwent radical right nephrectomy for a clear cell RCC (ccRCC). The biological tests showed pan-hypopituitarism and diabetes insipidus. Brain MRI revealed a large sellar tumor lesion bilaterally infiltrating the cavernous sinuses, which was surgically resected. Histology confirmed a ccRCC pituitary metastasis. The patient received post-surgical radiotherapy. Considering the presence of concomitant extra-pituitary metastases, treatment with sunitinib was started, followed by several lines of therapy with axitinib, everolimus, and sorafenib because of tumor progression. The patient also presented with a pituitary tumor recurrence, which was treated by stereotaxic radiotherapy. He died five years after the initial diagnosis of RCC and 30 months after the diagnosis of the pituitary metastasis. CONCLUSIONS There are no standardized treatment guidelines for management of pituitary metastases. Pituitary surgery plays a role in symptom palliation, and it does not have any relevant impact on survival. Exclusive radiotherapy or stereotaxic radiotherapy could be an alternative to surgery in patients whose general condition is poor or who have concomitant extra-pituitary metastases.
Collapse
Affiliation(s)
- Chloé Wendel
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Marco Campitiello
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Francesca Plastino
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Nada Eid
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Laurent Hennequin
- Division of Radiology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Philippe Quétin
- Division of Radiotherapy, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| | - Raffaele Longo
- Division of Medical Oncology, Regional Hospital Center (CHR) Metz-Thionville, Ars-Laquenexy, France
| |
Collapse
|
16
|
Longo R, Baptista BR, Campitiello M, Plastino F, Eid N, Caroline d Huart M, Klein L, Kull E, Hennequin L, Quetin P. Intra-luminal intestinal metastasis from malignant pleural mesothelioma. Australas Med J 2017. [DOI: 10.21767/amj.2017.3032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Dadduzio V, Basso M, Bensi M, Cona S, Cerchiaro E, Strippoli A, Campitiello M, Rossi S, Orlandi A, Plastino F, Calegari MA, Cassano A, Barone C, Semenova D. K-RAS codon 13 mutation in advanced colorectal cancer: A single-center retrospective study investigating prognostic outcomes and treatment strategies. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
633 Background: Ras genes are markers of resistance to anti-EGFR therapies. Emerging evidences suggest that each mutation, independently from its predictive role of response/resistance to specific treatments, may be expression of different diseases with different biologic behaviours. We collected data of mCRC patients harbouring K-Ras codon 13 mutation to evaluate response to therapy, PFS and OS. Methods: We retrospectively collected data of advanced colorectal cancer patients harbouring K-Ras codon 13 mutation treated at our Institution between 2004 and 2014. Results: A total of n.33 K-Ras codon 13 mutated patients were analysed. N.24 patients (72,7%) had synchronous metastatic disease. None of the patients received anti-EGFR treatment, while n.25 patients received anti-VEGF agent bevacizumab in association to chemotherapy with fluoropirimidines plus oxaliplatin and/or irinotecan (n.21 as frontline therapy, n.4 in second line). ORR was 51,5% (17/33) on first-line therapy, 22,2% (6/27) on second-line therapy and 16,6% (2/12) on third-line therapy. Median PFS was 14,1 months after first-line therapy, 9,3 months after second-line therapy, 6,4 months after third-line therapy. Median OS was 35,5 months (events: 19/33). N.14 patients received metastases surgery with radical intent. OS in this population has not been reached yet at a median follow-up of 38 months, even though all patients had a relapse. OS among patients undergone to systemic only strategy was 31 months. Conclusions: At our knowledge, this is the first report suggesting a favourable prognosis for K-ras codon 13 mutated patients, with a median overall survival even superior to pan-RAS wild-type patients. Indeed, the high percentage of advanced patients at diagnosis (72.7%), the high responsiveness to chemotherapy even in third line, the high percentage of patients converted to surgery (42.4%) in an unselected population, together with the high risk or relapse after surgery, suggest K-ras codon 13 mutated disease is probably a biologically aggressive disease. Nevertheless our data prompt that these patients may benefit aggressive strategies of treatment and multidisciplinary evaluation.
Collapse
Affiliation(s)
| | - Michele Basso
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | - Maria Bensi
- Medical Oncology, Catholic University of Sacred Heart, Roma, Italy
| | - Silvia Cona
- Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
| | | | | | | | - Sabrina Rossi
- Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
| | - Armando Orlandi
- Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
| | | | | | | | - Carlo Barone
- Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
| | - Diana Semenova
- Medical Oncology, Catholic University of Sacred Heart, Rome, Italy
| |
Collapse
|
18
|
Orlandi A, Di Salvatore M, Bagalà C, Basso M, Strippoli A, Plastino F, Calegari MA, Cassano A, Astone A, Barone C. ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. J Cancer 2015; 6:70-81. [PMID: 25553091 PMCID: PMC4278917 DOI: 10.7150/jca.10478] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 11/16/2014] [Indexed: 11/25/2022] Open
Abstract
Introduction: Oxaliplatin (Oxa) is widely used in metastatic colorectal cancer (mCRC), but currently there are not valid predictors of response to this drug. In the control arms both of OPUS and PRIME studies Oxa seems more active in patients with mCRC with mutated (mt) KRAS than in those with wild type (wt) KRAS. Recently we have retrospectively confirmed this suggestion, therefore we have hypothesized that the mutational status of KRAS could influence the expression of ERCC1, one of the main mechanisms of Oxa resistance. Material and Methods: We used four cell lines of colorectal cancer: two KRAS wild type (wt) (HCT-8 and HT-29) and two KRAS mt (SW620 and SW480). We evaluated the sensitivity of these cell lines to Oxa by MTT-test as well the ERCC1 levels before and after 24 h exposure to Oxa by Real-Time PCR. We silenced KRAS in a KRAS mt cell line (SW620LV) to evaluate the impact on Oxa sensitivity and ERCC1 levels. Lastly, ERCC1 was also silenced in order to confirm the importance of this protein as an Oxa resistance factor. Results: The KRAS mt cell lines resulted more sensitive to Oxa (OR 2.68; IC 95% 1.511-4.757 p<0.001). The basal levels of ERCC1 did not show significant differences between KRAS mt and wt cell lines, however, after 24 h exposure to Oxa, only the wt KRAS lines showed the ability to induce ERCC1, with a statistically significant difference (OR 42.9 IC 95% 17.260-106.972 p<0.0005). By silencing KRAS, sensitivity to Oxa was reduced in mt KRAS cell lines and this effect was associated with the acquisition of ability to induce ERCC1. Silencing of ERCC1, in turn, enhanced the sensitivity to Oxa in wt KRAS cell lines and restored sensitivity to Oxa in SW620LV cell line. Conclusion: KRAS mutated cell lines were more sensitive to Oxa. This feature seems secondary to the inability of these cells to induce ERCC1 after exposure to Oxa. Thus, KRAS mutational status might be a predictor of response to Oxa in CRC surrogating the cell ability to induce ERCC1.
Collapse
Affiliation(s)
- A Orlandi
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M Di Salvatore
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - C Bagalà
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M Basso
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Strippoli
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - F Plastino
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M A Calegari
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Cassano
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Astone
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - C Barone
- Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
19
|
Treglia G, Plastino F, Campitiello M. Staging and treatment response evaluation in a metastatic neuroendocrine tumor of the pancreas with G2 grading: insights from multimodality diagnostic approach by F-18-FDG and Ga-68-DOTANOC PET/CT. Endocrine 2013; 43:729-31. [PMID: 23247870 DOI: 10.1007/s12020-012-9858-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2012] [Accepted: 12/05/2012] [Indexed: 10/27/2022]
Affiliation(s)
- Giorgio Treglia
- Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo A. Gemelli 8, 00168, Rome, Italy.
| | | | | |
Collapse
|
20
|
Orlandi A, Di Salvatore M, Basso M, Bagalà C, Strippoli A, Plastino F, Dadduzio E, Di Lascio S, Cursio E, Amoruso A, Rodriquenz M, Cassano A, Astone A, Barone C. ERCC1, KRAS mutation, redox status, and oxaliplatin sensitivity in colorectal cancer: “Radical” change in an old model. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.e14156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14156 Background: Oxaliplatin (Oxa) is widely used in metastatic colorectal cancer, but currently there are not valid predictors of response to this drug. In our recent retrospective clinical study we have shown a greater efficacy of Oxa in patients with metastatic colorectal cancer with mutated (mt) K-RAS. We hypothesized that the mutational status of K-RAS could influence the expression of ERCC1 and cellular Redox status. Methods: We used four cell lines of colorectal cancer: two K-RAS wild type (wt) (HCT-8, HT-29) and two K-RAS mt (SW620, SW480). We evaluated the sensitivity of these cell lines to Oxa by MTT-test and the ERCC1 levels before and after 24h exposure to Oxa by RT-PCR. We silenced K-RAS in a K-RAS mt cell lines to evaluate the impact on Oxa sensitivity and ERCC1 levels. We also silenced ERCC1 in order to confirm the importance of this protein as a Oxa resistance factor. Cellular oxidative stress was determined by DCFDA. Results: The K-RAS mt cell lines were more sensitive to Oxa (p<0.001). The basal levels of ERCC1 did not show significant differences between K-RAS mt and wt cell line, however, after 24h exposure to Oxa, only the K-RAS wt lines showed the ability to induce ERCC1, with a statistically significant difference (p<0.005). The silencing of K-RAS in K-RAS mt cell lines (SW620s) demonstrated to reduce sensitivity to Oxa associated with the acquisition of the ability to induce ERCC1. The silencing of ERCC1 in K-RAS wt cell lines enhance the sensibility to Oxa. The levels of reactive oxygen species were higher in K-RAS mt cell lines. The Pearson correlation test showed a statistically significant relationship between basal levels of ROS and sensitivity to Oxa ("r" -0,988, p<0.01). The baseline levels of ROS were higher SW620 than the line SW620s. The administration of Oxa in these cell lines resulted in a statistically higher fluorescence index in SW620 versus SW620s (p<0.003). Conclusions: The K-RAS mutated cell lines were more sensitive to Oxa. This feature seems to be secondary to the inability of these cells to induce ERCC1 after exposure to Oxa and to the synergism between K-RAS mutation and Oxa in increasing oxidative stress. K-RAS can thus be a predictor of response to Oxa in colorectal cancer.
Collapse
Affiliation(s)
- Armando Orlandi
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | | | - Michele Basso
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | - Cinzia Bagalà
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | - Antonia Strippoli
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | | | | | | | | | - Alessia Amoruso
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | | | | | - Antonio Astone
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy
| | - Carlo Barone
- Catholic University of Sacred Heart, Rome, Italy
| |
Collapse
|
21
|
Orlandi A, Di Salvatore M, Basso M, Bagalà C, Strippoli A, Plastino F, Dadduzio E, Di Lascio S, Quirino M, Cassano A, Astone A, Barone C. ERCC1, KRAS mutation, and oxaliplatin sensitivity in colorectal cancer: Old dogs and new tricks. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.4_suppl.489] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
489 Background: Oxaliplatin is widely used in metastatic colorectal cancer, but currently there are not valid predictors of response to this drug. In our recent retrospective clinical study we have shown a greater efficacy of Oxaliplatin in patients with metastatic colorectal cancer with mutated (mt) K-RAS. We hypothesized that the mutational status of K-RAS could influence the expression of ERCC1, one of the main mechanisms of Oxaliplatin resistance. Methods: We used four cell lines of colorectal cancer: two K-RAS wild type (wt) (HCT-8 and HT-29) and two K-RAS mt (SW620 and SW480). We evaluated the sensitivity of these cell lines to Oxaliplatin by MTT-test and the ERCC1 levels before and after 24 h exposure to Oxaliplatin by Real-Time PCR. We silenced K-RAS in a K-RAS mt cell line to evaluate the impact on Oxaliplatin sensitivity and ERCC1 levels. We also silenced ERCC1 in order to confirm the importance of this protein as a Oxaliplatin resistance factor. Results: The K-RAS mt cell lines were more sensitive to Oxaliplatin (OR 2.68; IC 95% 1.511-4.757 p<0.001). The basal levels of ERCC1 did not show significant differences between K-RAS mt and wt cell line, however, after 24 h exposure to Oxaliplatin, only the K-RAS wt lines showed the ability to induce ERCC1, with a statistically significant difference (OR 42.9 IC 95% 17.260-106.972 p<0.0005). The silencing of K-RAS in K-RAS mt cell lines demonstrated to reduce sensitivity to Oxaliplatin associated with the acquisition of the ability to induce ERCC1. The silencing of ERCC1 in K-RAS wt cell lines enhance the sensibility to Oxaliplatin. Conclusions: The K-RAS mutated cell lines were more sensitive to Oxaliplatin. This feature seems to be secondary to the inability of these cells to induce ERCC1 after exposure to Oxaliplatin. K-RAS can thus be a predictor of response to Oxaliplatin in colorectal cancer representing a surrogate for ability to induce ERCC1.
Collapse
Affiliation(s)
- Armando Orlandi
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Mariantonietta Di Salvatore
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Michele Basso
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Cinzia Bagalà
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Antonia Strippoli
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Francesca Plastino
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Enzo Dadduzio
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Simona Di Lascio
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Michela Quirino
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Alessandra Cassano
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Antonio Astone
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| | - Carlo Barone
- Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Catholic University of Sacred Heart , Roma, Italy; Casred Heart Catholic University, Roma, Italy
| |
Collapse
|